This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Pharmaceutical Companies Remove Presentation Remove Process Improvement
article thumbnail

Developing a first-in-class small molecule drug for inflammatory disease

European Pharmaceutical Review

NOVEMBER 9, 2023

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

Pharmaceutical Companies 115
Pharmaceutical Companies Pharmaceutical Companies Immunization Process Improvement 115
article thumbnail

An Evaluation of Postapproval CMC Change Timelines

ISPE

SEPTEMBER 10, 2023

In addition to delaying optimization of manufacturing and controls, these types of long delays for approvals discourage continuous process improvements for approved products. Then the durations were compiled for analysis and presented in the table. Table 1: Hypothetical example of how an assessment was performed.

Documentation 98
Documentation Process Improvement Packaging Pharmaceutical Companies 98
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 5,000+ Insiders by signing up for our newsletter

About
Webinars
About
Editions
Webinars
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024